This scoping review examines the role of global health partnerships (GHPs) in promoting vaccine equity, focusing on their emergence, mechanisms, and challenges. GHPs, which include collaborations between governments, philanthropic foundations, NGOs, and international agencies, aim to incentivize vaccine development, raise funds, and support delivery systems. The review identifies key themes such as policy responses, different forms of partnerships in vaccine innovation, and their influence on global governance decision-making processes. Despite their efforts, GHPs face challenges such as donor fatigue, lack of transparency, and the need for health systems strengthening. The review suggests that to maximize their contributions, GHPs should increase transparency, address health system strengthening, and encourage cooperative vaccine R&D partnerships and manufacturing capacity expansion in low- and middle-income countries (LMICs). The findings highlight the importance of understanding how GHPs can be leveraged to achieve global vaccine equity, particularly in high-income economies, and the need for further research to identify effective mechanisms for collaboration among global health governance actors.This scoping review examines the role of global health partnerships (GHPs) in promoting vaccine equity, focusing on their emergence, mechanisms, and challenges. GHPs, which include collaborations between governments, philanthropic foundations, NGOs, and international agencies, aim to incentivize vaccine development, raise funds, and support delivery systems. The review identifies key themes such as policy responses, different forms of partnerships in vaccine innovation, and their influence on global governance decision-making processes. Despite their efforts, GHPs face challenges such as donor fatigue, lack of transparency, and the need for health systems strengthening. The review suggests that to maximize their contributions, GHPs should increase transparency, address health system strengthening, and encourage cooperative vaccine R&D partnerships and manufacturing capacity expansion in low- and middle-income countries (LMICs). The findings highlight the importance of understanding how GHPs can be leveraged to achieve global vaccine equity, particularly in high-income economies, and the need for further research to identify effective mechanisms for collaboration among global health governance actors.